ÂÜÀòÂÒÂ×

Arthur Klausner is an experienced life science venture capitalist and company executive. He earned his M.B.A. from the Stanford University Graduate School of Business and his B.A. in Biology from Princeton University. He was previously CEO and a board member of Gem Pharmaceuticals and CEO and a board member of Jade Therapeutics. He has spent a total of 18 years as a life sciences venture capitalist at Domain Associates and Pappas Ventures. He currently serves on the Board of Directors of Monopar Therapeutics (Nasdaq: MNPR), and on the Life Sciences Investment Review Board for the New York University Innovation Venture Fund. He currently serves as the President and CEO of Goldilocks Therapeutics, Inc.